Pathogenesis of irritable bowel syndrome - Review regarding associated infection and immune activation

Digestion

Volumn 87, Issue 3, 2013, Pages 204-211

  Ishihara, Shunji ^a   Tada, Yasumasa ^a   Fukuba, Nobuhiko ^a   Oka, Akihiko ^a   Kusunoki, Ryusaku ^a   Mishima, Yoshiyuki ^a   Oshima, Naoki ^a   Moriyama, Ichiro ^a   Yuki, Takafumi ^a   Kawashima, Kousaku ^a   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Immune activation; Irritable bowel syndrome; Toll like receptors

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; INTERLEUKIN 1BETA; TOLL LIKE RECEPTOR;

ACUTE GASTROENTERITIS; CAMPYLOBACTER ENTERITIS; DISEASE ASSOCIATION; GASTROENTERITIS; HUMAN; IMMUNITY; INNATE IMMUNITY; INTESTINE INFECTION; IRRITABLE COLON; LEUKOCYTE ACTIVATION; MENTAL STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SALMONELLOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; B LYMPHOCYTE; DNA POLYMORPHISM; IMMUNOCOMPETENT CELL; MACROPHAGE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RISK FACTOR; T LYMPHOCYTE;

ANIMALS; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFECTION; IRRITABLE BOWEL SYNDROME; TOLL-LIKE RECEPTORS;

EID: 84878099761     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000350054     Document Type: Review

References (78)

1. Cremonini F, Talley NJ: Irritable bowel syndrome: Epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005; 34: 189-204.
2. Talley NJ: Irritable bowel syndrome. Intern Med J 2006; 36: 724-728.
3. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P: Clinical Services Committee of The British Society of Gastroenterology. Guidelines on the irritable bowel syndrome: Mechanisms and practical management. Gut 2007; 56: 1770-1798.
4. Spiller R: Clinical update: Irritable bowel syndrome. Lancet 2007; 369: 1586-1588.
5. Dang J, Ardila-Hani A, Amichai MM, Chua K, Pimentel M: Systematic review of diagnostic criteria for IBS demonstrates poor validity and utilization of Rome III: NEUROGASTROENTEROL Motil 2012; 24: 853-e397.
6. Surdea-Blaga T, Bǎ;ban A, Dumitrascu DL: Psychosocial determinants of irritable bowel syndrome. World J Gastroenterol 2012; 18: 616-626.
7. Fukudo S, Kuwano H, Miwa H: Management and pathophysiology of functional gastrointestinal disorders. Digestion 2012; 85: 85-89.
8. Bashashati M, Rezaei N, Bashashati H, Shafieyoun A, Daryani NE, Sharkey KA, Storr M: Cytokine gene polymorphisms are associated with irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil 2012; 24: 1102-e566.
9. Ohman L, Simrén M: Pathogenesis of IBS: Role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-173.
10. El-Salhy M: Irritable bowel syndrome: Diagnosis and pathogenesis. World J Gastroenterol 2012; 18: 5151-5163.
11. Spiller R, Lam C: The shifting interface between IBS and IBD. Curr Opin Pharmacol 2011; 116: 586-592.
12. Elsenbruch S: Abdominal pain in irritable bowel syndrome: A review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011; 25: 386-394.
13. Bashashati M, Rezaei N, Andrews CN, Chen CQ, Daryani NE, Sharkey KA, Storr MA: Cytokines and irritable bowel syndrome: Where do we stand? Cytokine 2012; 572: 201-209.
14. Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, Ardid D: Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36: 1009-1031.
15. Stasi C, Rosselli M, Bellini M, Laffi G, Milani S: Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: The topdown and the bottom-up model. J Gastroenterol 2012; 47: 1177-1185.
16. Ford AC, Talley NJ: Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: A systematic review. J Gastroenterol 2011; 46: 421-431.
17. Qin HY, Wu JC, Tong XD, Sung JJ, Xu HX, Bian ZX: Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome. J Gastroenterol 2011; 462: 164-174.
18. Dupont AW: Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep 2007; 9: 378-384.
19. Rhodes DY, Wallace M: Post-infectious irritable bowel syndrome. Curr Gastroenterol Rep 2006; 8: 327-332.
20. Spiller R, Lam C: An update on post-infectious irritable bowel syndrome: Role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 2012; 18: 258-268.
21. Thabane M, Kottachchi DT, Marshall JK: Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-544.
22. Ishihara S, Aziz M, Oshima N, Mishima Y, Imaoka H, Moriyama I, Kinoshita Y: Irritable bowel syndrome and inflammatory bo wel disease: Infectious gastroenteritis-related disorders? Clin J Gastroenterol 2009; 2: 9-16.
23. Ohman L, Isaksson S, Lindmark AC, Posserud I, Stotzer PO, Strid H, Sjövall H, Simrén M: T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 1205-1212.
24. Ohman L, Isaksson S, Lundgren A, Simrén M, Sjövall H: A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 980-986.
25. Ohman L, Lindmark AC, Isaksson S, Posserud I, Strid H, Sjövall H, Simrén M: B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2009; 21: 644-650, e27.
26. Elsenbruch S, Holtmann G, Oezcan D, Lysson A, Janssen O, Goebel MU, Schedlowski M: Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am J Gastroenterol 2004; 99: 703-710.
27. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW: Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: Plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-311.
28. Dinan TG, Clarke G, Quigley EM, Scott LV, Shanahan F, Cryan J, Cooney J, Keeling PW: Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: Role of muscarinic receptors. Am J Gastroenterol 2008; 103: 2570-2576.
29. Scully P, McKernan DP, Keohane J, Groeger D, Shanahan F, Dinan TG, Quigley EM: Plasma cytokine profiles in females with irritable bowel syndrome and extra-intestinal co-morbidity. Am J Gastroenterol 2010; 105: 2235-2243.
30. Goral V, Kucukoner M, Buyukbayram H: Mast cells count and serum cytokine levels in patients with irritable bowel syndrome. Hepatogastroenterology 2010; 57: 751-754.
31. Del Valle-Pinero AY, Martino AC, Taylor TJ, Majors BL, Patel NS, Heitkemper MM, Henderson WA: Pro-inflammatory chemokine C-C motif ligand 16 (CCL-16) dysregulation in irritable bowel syndrome (IBS): A pilot study. Neurogastroenterol Motil 2011; 23: 1092-1097.
32. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM: Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551.
33. Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G: Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920.
34. Kindt S, Van Oudenhove L, Broekaert D, Kasran A, Ceuppens JL, Bossuyt X, Fischler B, Tack J: Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009; 21: 389-398.
35. Macsharry J, Mahony A, Fanning E, Bairead G, Sherlock J, Tiesman J, Fulmer A, Kiely B, Dinan TG, Shanahan F, Quigley EM: Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-1476.
36. Gwee KA, Collins SM, Read NW, Rajnakova A, Deng Y, Graham JC, McKendrick MW, Moochhala SM: Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003; 52: 523-526.
37. Kim HS, Lim JH, Park H, Lee SI: Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection - an observation in a small case control study. Yonsei Med J 2010; 51: 45-51.
38. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R: Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702.
39. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R: Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37.
40. Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G: Mucosal immune activation in irritable bowel syndrome: Gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009; 104: 392-400.
41. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA: Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-457.
42. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I: Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783.
43. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martínez C, Casellas F, Saperas E, Malagelada JR: Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-209.
44. Foley S, Garsed K, Singh G, Duroudier NP, Swan C, Hall IP, Zaitoun A, Bennett A, Marsden C, Holmes G, Walls A, Spiller RC: Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology 2011; 140: 1434-1443.
45. Goral V, Kucukoner M, Buyukbayram H: Mast cells count and serum cytokine levels in patients with irritable bowel syndrome. Hepatogastroenterology 2010; 57: 751-754.
46. Wang SH, Dong L, Luo JY, Gong J, Li L, Lu XL, Han SP: Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol 2007; 13: 6041-6047.
47. Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW: The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008; 23: 1689-1694.
48. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW: The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-406.
49. Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC: Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006; 21: 71-78.
50. Piche T, Saint-Paul MC, Dainese R, Marine-Barjoan E, Iannelli A, Montoya ML, Peyron JF, Czerucka D, Cherikh F, Filippi J, Tran A, Hébuterne X: Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008; 57: 468-473.
51. Dunlop SP, Jenkins D, Spiller RC: Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98: 1578-1583.
52. Törnblom H, Lindberg G, Nyberg B, Veress B: Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002; 123: 1972-1979.
53. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811.
54. Forshammar J, Isaksson S, Strid H, Stotzer PO, Sjövall H, Simrén M, Ohman L: A pilot study of colonic B cell pattern in irritable bowel syndrome. Scand J Gastroenterol 2008; 29: 1-6.
55. Park KS, Ahn SH, Hwang JS, Cho KB, Chung WJ, Jang BK, Kang YN, Kwon JH, Kim YH: A survey about irritable bowel syndrome in South Korea: Prevalence and observable organic abnormalities in IBS patients. Dig Dis Sci 2008; 53: 704-711.
56. Wang LH, Fang XC, Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-1101.
57. Chen J, Zhang Y, Deng Z: Imbalanced shift of cytokine expression between T helper 1 and T helper 2 (Th1/Th2) in intestinal mucosa of patients with post-infectious irritable bowel syndrome. BMC Gastroenterol 2012; 12: 91.
58. Camilleri M, Lasch K, Zhou W: Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 303:G775-G785.
59. Barkhordari E, Rezaei N, Mahmoudi M, Larki P, Ahmadi-Ashtiani HR, Ansaripour B, Alighardashi M, Bashashati M, Amirzargar AA, Ebrahimi-Daryani N: T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome. Inflammation 2010; 33: 281-286.
60. Barkhordari E, Rezaei N, Ansaripour B, Larki P, Alighardashi M, Ahmadi-Ashtiani HR, Mahmoudi M, Keramati MR, Habibollahi P, Bashashati M, Ebrahimi-Daryani N, Amirzargar AA: Proinflammatory cytokine gene polymorphisms in irritable bowel syndrome. J Clin Immunol 2010; 30: 74-79.
61. Villani AC, Lemire M, Thabane M, Belisle A, Geneau G, Garg AX, Clark WF, Moayyedi P, Collins SM, Franchimont D, Marshall JK: Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010; 138: 1502-1513.
62. Medzhitov R, Janeway CA Jr: Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298-300.
63. Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
64. Aderem A, Ulevitch RJ: Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-787.
65. Underhill DM, Ozinsky A: Toll-like receptors: Key mediators of microbe detection. Curr Opin Immunol 2002; 14: 103-110.
66. Kopp E, Medzhitov R: Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 2003; 15: 396-401.
67. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaële N, Antonietti M, Lecleire S, Zalar A, Gourcerol G, Leroi AM, Déchelotte P, Coëffier M, Ducrotté P: Role of Toll-like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7:e42777.
68. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM: Differential expression of Toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011; 106: 329-336.
69. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaële N, Antonietti M, Lecleire S, Zalar A, Gourcerol G, Leroi AM, Déchelotte P, Coëffier M, Ducrotté P: Role of Toll-like receptors in irritable bowel syndrome: Differential mucosal immune activation according to the disease subtype. PLoS One 2012; 7:e42777.
70. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG: Altered peripheral Toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1045-1052.
71. Hua MC, Lai MW, Kuo ML, Yao TC, Huang JL, Chen SM: Decreased interleukin-10 secretion by peripheral blood mononuclear cells in children with irritable bowel syndrome. J Pediatr Gastroenterol Nutr 2011; 52: 376-381.
72. Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F: Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008; 20: 1110-1118.
73. Cremon C, Pallotti F, Bacchilega M, Stanghellini V, Corinaldesi R, Barbara G: Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. Expert Rev Gastroenterol Hepatol 2008; 2: 735-740.
74. Alonso C, Guilarte M, Vicario M, Ramos L, Ramadan Z, Antolín M, Martínez C, Rezzi S, Saperas E, Kochhar S, Santos J, Malagelada JR: Maladaptive intestinal epithelial responses to life stress may predispose healthy women to gut mucosal inflammation. Gastroenterology 2008; 135: 163-172.
75. Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ: Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol 2009; 104: 404-410.
76. Elsenbruch S: Abdominal pain in irritable bowel syndrome: A review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011; 25: 386-394.
77. McKernan DP, Nolan A, Brint EK, O'Mahony SM, Hyland NP, Cryan JF, Dinan TG: Tolllike receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome. PLoS One 2009; 4:e8226.
78. Bailey MT, Engler H, Powell ND, Padgett DA, Sheridan JF: Repeated social defeat increases the bactericidal activity of splenic macrophages through a Toll-like receptor-dependent pathway. Am J Physiol Regul Integr Comp Physiol 2007; 293:R1180-R1190.